BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol 2020;73:451-3. [PMID: 32278005 DOI: 10.1016/j.jhep.2020.03.044] [Cited by in Crossref: 191] [Cited by in F6Publishing: 185] [Article Influence: 95.5] [Reference Citation Analysis]
Number Citing Articles
1 Pasha SB, Swi A, Hammoud GM. Gastrointestinal and hepatic manifestations of COVID-19 infection: Lessons for practitioners. World J Meta-Anal 2020; 8(5): 348-374 [DOI: 10.13105/wjma.v8.i5.348] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Metawea MI, Yousif WI, Moheb I. COVID 19 and liver: An A-Z literature review. Dig Liver Dis. 2021;53:146-152. [PMID: 32988758 DOI: 10.1016/j.dld.2020.09.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
3 Liu M, Mei K, Tan Z, Huang S, Liu F, Deng C, Ma J, Yu P, Liu X, Marasco G. Liver Fibrosis Scores and Hospitalization, Mechanical Ventilation, Severity, and Death in Patients with COVID-19: A Systematic Review and Dose-Response Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-11. [DOI: 10.1155/2022/7235860] [Reference Citation Analysis]
4 Sachdeva S, Khandait H, Kopel J, Aloysius MM, Desai R, Goyal H. NAFLD and COVID-19: a Pooled Analysis. SN Compr Clin Med. 2020;1-4. [PMID: 33173850 DOI: 10.1007/s42399-020-00631-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
5 Idalsoaga F, Ayares G, Arab JP, Díaz LA. COVID-19 and Indirect Liver Injury: A Narrative Synthesis of the Evidence. J Clin Transl Hepatol 2021;9:760-8. [PMID: 34722191 DOI: 10.14218/JCTH.2020.00140] [Reference Citation Analysis]
6 Baroiu L, Dumitru C, Iancu A, Leșe AC, Drăgănescu M, Baroiu N, Anghel L. COVID-19 impact on the liver. World J Clin Cases 2021; 9(16): 3814-3825 [PMID: 34141738 DOI: 10.12998/wjcc.v9.i16.3814] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Kroemer A, Khan K, Plassmeyer M, Alpan O, Haseeb MA, Gupta R, Fishbein TM. Inflammasome activation and pyroptosis in lymphopenic liver patients with COVID-19. J Hepatol 2020;73:1258-62. [PMID: 32645361 DOI: 10.1016/j.jhep.2020.06.034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
8 Sagnelli C, Macera M, Camaioni C, Salvati A, Coppola N, Sagnelli E. SARS-CoV-2 infection: a hurricane that does not ignore chronic hepatitis. Infection 2022. [PMID: 35316530 DOI: 10.1007/s15010-022-01804-z] [Reference Citation Analysis]
9 Hamid S, Alvares da Silva MR, Burak KW, Chen T, Drenth JPH, Esmat G, Gaspar R, LaBrecque D, Lee A, Macedo G, McMahon B, Ning Q, Reau N, Sonderup M, van Leeuwen DJ, Armstrong D, Yurdaydin C. WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. J Clin Gastroenterol. 2021;55:1-11. [PMID: 33230011 DOI: 10.1097/mcg.0000000000001459] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
10 Targher G, Mantovani A, Byrne CD, Wang X, Yan H, Sun Q, Pan K, Zheng KI, Chen Y, Eslam M, George J, Zheng M. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut 2020;69:1545-7. [DOI: 10.1136/gutjnl-2020-321611] [78495111110.1136/gutjnl-2020-321611','', '1007-9327')">Reference Citation Analysis]
11 Zhou YJ, Zheng KI, Wang XB, Yan HD, Sun QF, Pan KH, Wang TY, Ma HL, Chen YP, George J, Zheng MH. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis. J Hepatol. 2020;73:719-721. [PMID: 32348790 DOI: 10.1016/j.jhep.2020.04.027] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 25.5] [Reference Citation Analysis]
12 Cardinale V, Capurso G, Ianiro G, Gasbarrini A, Arcidiacono PG, Alvaro D. Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: A working hypothesis. Dig Liver Dis 2020;52:1383-9. [PMID: 33023827 DOI: 10.1016/j.dld.2020.09.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
13 Elfeki MA, Robles J, Akhtar Z, Ullah F, Ganapathiraju I, Tran C, Inman C, Collin SM, Rosa R. Impact of Fibrosis-4 Index Prior to COVID-19 on Outcomes in Patients at Risk of Non-alcoholic Fatty Liver Disease. Dig Dis Sci 2021. [PMID: 34173917 DOI: 10.1007/s10620-021-07120-0] [Reference Citation Analysis]
14 Ekpanyapong S, Bunchorntavakul C, Reddy KR. COVID-19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later. J Viral Hepat 2021. [PMID: 34352133 DOI: 10.1111/jvh.13590] [Reference Citation Analysis]
15 Mushtaq K, Khan MU, Iqbal F, Alsoub DH, Chaudhry HS, Ata F, Iqbal P, Elfert K, Balaraju G, Almaslamani M, Al-Ejji K, AlKaabi S, Kamel YM. NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues. J Hepatol 2021;74:482-4. [PMID: 33223215 DOI: 10.1016/j.jhep.2020.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
16 Campos-Varela I, Villagrasa A, Simon-Talero M, Riveiro-Barciela M, Ventura-Cots M, Aguilera-Castro L, Alvarez-Lopez P, Nordahl EA, Anton A, Bañares J, Barber C, Barreira-Diaz A, Biagetti B, Camps-Relats L, Ciudin A, Cocera R, Dopazo C, Fernandez A, Jimenez C, Jimenez MM, Jofra M, Gil C, Gomez-Gavara C, Guanozzi D, Guevara JA, Lobo B, Malagelada C, Martinez-Camprecios J, Mayorga L, Miret E, Pando E, Pérez-Lopez A, Pigrau M, Prio A, Rivera-Esteban JM, Romero A, Tasayco S, Vidal-Gonzalez J, Vidal L, Minguez B, Augustin S, Genesca J. The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19. Therap Adv Gastroenterol 2021;14:17562848211016567. [PMID: 34104210 DOI: 10.1177/17562848211016567] [Reference Citation Analysis]
17 Leo M, Galante A, Pagnamenta A, Ruinelli L, Ponziani F, Gasbarrini A, De Gottardi A. Hepatocellular liver injury in hospitalized patients affected by COVID-19: presence of different risk factors at different time points. Digestive and Liver Disease 2021. [DOI: 10.1016/j.dld.2021.12.014] [Reference Citation Analysis]
18 Váncsa S, Hegyi PJ, Zádori N, Szakó L, Vörhendi N, Ocskay K, Földi M, Dembrovszky F, Dömötör ZR, Jánosi K, Rakonczay Z Jr, Hartmann P, Horváth T, Erőss B, Kiss S, Szakács Z, Németh D, Hegyi P, Pár G. Pre-existing Liver Diseases and On-Admission Liver-Related Laboratory Tests in COVID-19: A Prognostic Accuracy Meta-Analysis With Systematic Review. Front Med (Lausanne) 2020;7:572115. [PMID: 33282888 DOI: 10.3389/fmed.2020.572115] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
19 Vavougios GD. Human coronaviruses in idiopathic Parkinson's disease: Implications of SARS-CoV-2's modulation of the host's transcriptome. Infect Genet Evol 2021;89:104733. [PMID: 33516970 DOI: 10.1016/j.meegid.2021.104733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Khoonsari M, Zamani F, Karbalaie Niya MH, Hemmasi G, Ajdarkosh H, Faraji A, Nikkhah M, Pishgar E, Jamshidi Makiani M, Ranjbar M, Safarnezhad Tameshkel F, Panahi M, Ameli M, Yadollahzadeh M, Farrokhpour M, Maadi M, Ghafari A, Valuiyan M, Pouladi M, Motamed N. Liver Enzymes and Inpatient Deaths in COVID-19 Hospitalized Patients. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.109076] [Reference Citation Analysis]
21 Ji D, Qin E, Zhang D, Cheng G, Lau G. Reply to author. Clin Infect Dis 2020:ciaa1568. [PMID: 33063818 DOI: 10.1093/cid/ciaa1568] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
22 Yang HY, Jin B, Mao YL. Liver injury in COVID-19: What do we know now? Hepatobiliary Pancreat Dis Int. 2020;19:407-408. [PMID: 32753332 DOI: 10.1016/j.hbpd.2020.07.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Meijnikman AS, Bruin S, Groen AK, Nieuwdorp M, Herrema H. Increased expression of key SARS-CoV-2 entry points in multiple tissues in individuals with NAFLD. J Hepatol 2021;74:748-9. [PMID: 33338513 DOI: 10.1016/j.jhep.2020.12.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
24 Fancellu A, Sanna V, Scognamillo F, Feo CF, Vidili G, Nigri G, Porcu A. Surgical treatment of hepatocellular carcinoma in the era of COVID-19 pandemic: A comprehensive review of current recommendations. World J Clin Cases 2021; 9(15): 3517-3530 [PMID: 34046452 DOI: 10.12998/wjcc.v9.i15.3517] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Amin M. COVID-19 and the liver: overview. Eur J Gastroenterol Hepatol 2021;33:309-11. [PMID: 32558697 DOI: 10.1097/MEG.0000000000001808] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
26 Xu Y, Yang X, Bian H, Xia M. Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management. Lipids Health Dis 2021;20:126. [PMID: 34602072 DOI: 10.1186/s12944-021-01564-z] [Reference Citation Analysis]
27 Liu F, Long X, Ji G, Zhang B, Zhang W, Zhang Z, Chen X. Clinically significant portal hypertension in cirrhosis patients with COVID-19: Clinical characteristics and outcomes. J Infect. 2020;81:e178-e180. [PMID: 32562796 DOI: 10.1016/j.jinf.2020.06.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
28 Ngiam JN, Chew N, Tham SM, Lim ZY, Li TY, Cen S, Tambyah PA, Santosa A, Muthiah M, Sia CH, Cross GB. Elevated liver enzymes in hospitalized patients with COVID-19 in Singapore. Medicine (Baltimore) 2021;100:e26719. [PMID: 34397705 DOI: 10.1097/MD.0000000000026719] [Reference Citation Analysis]
29 Yu D, Du Q, Yan S, Guo XG, He Y, Zhu G, Zhao K, Ouyang S. Liver injury in COVID-19: clinical features and treatment management. Virol J 2021;18:121. [PMID: 34108015 DOI: 10.1186/s12985-021-01593-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Cava C, Bertoli G, Castiglioni I. A protein interaction map identifies existing drugs targeting SARS-CoV-2. BMC Pharmacol Toxicol 2020;21:65. [PMID: 32883368 DOI: 10.1186/s40360-020-00444-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
31 Bellanti F, Vendemiale G. Coronavirus disease 2019 and non-alcoholic fatty liver disease. World J Hepatol 2021; 13(9): 969-978 [PMID: 34630869 DOI: 10.4254/wjh.v13.i9.969] [Reference Citation Analysis]
32 Lin J, Bao B, Khurram NA, Halsey K, Choi JW, Wang L, Tran TML, Liao WH, Feldman MD, Zhang PJ, Wu J, Bai HX. Chronic liver disease not a significant comorbid condition for COVID-19. Sci Rep 2021;11:11734. [PMID: 34083670 DOI: 10.1038/s41598-021-91238-8] [Reference Citation Analysis]
33 Al-Nimer MS. Is COVID-19-induced liver injury different from other RNA viruses?‎ World J Meta-Anal 2021; 9(2): 108-127 [DOI: 10.13105/wjma.v9.i2.108] [Reference Citation Analysis]
34 Taneja S, Mehtani R, Chawla YK. Gastrointestinal and Liver Manifestations of COVID-19. Annals of the National Academy of Medical Sciences (India) 2020;56:091-8. [DOI: 10.1055/s-0040-1713837] [Reference Citation Analysis]
35 Xiang F, Sun J, Chen PH, Han P, Zheng H, Cai S, Kirk GD. Early Elevation of Fibrosis-4 Liver Fibrosis Score Is Associated With Adverse Outcomes Among Patients With Coronavirus Disease 2019. Clin Infect Dis 2021;73:e594-601. [PMID: 33909004 DOI: 10.1093/cid/ciaa1710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
36 Zhou F, Xia J, Yuan HX, Sun Y, Zhang Y. Liver injury in COVID-19: Known and unknown. World J Clin Cases 2021; 9(19): 4980-4989 [PMID: 34307548 DOI: 10.12998/wjcc.v9.i19.4980] [Reference Citation Analysis]
37 Su TH, Kao JH. The clinical manifestations and management of COVID-19-related liver injury. J Formos Med Assoc 2020;119:1016-8. [PMID: 32345544 DOI: 10.1016/j.jfma.2020.04.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
38 Gaspar R, Castelo Branco C, Macedo G. Liver and COVID-19: From care of patients with liver diseases to liver injury. World J Hepatol 2021; 13(10): 1367-1377 [PMID: 34786172 DOI: 10.4254/wjh.v13.i10.1367] [Reference Citation Analysis]
39 Ma Y, Zhu DS, Chen RB, Shi NN, Liu SH, Fan YP, Wu GH, Yang PY, Bai JF, Chen H, Chen LY, Feng Q, Guo TM, Hou Y, Hu GF, Hu XM, Hu YH, Huang J, Huang QH, Huang SZ, Ji L, Jin HH, Lei X, Li CY, Li MQ, Li QT, Li XY, Liu H, Liu JP, Liu Z, Ma YT, Mao Y, Mo LF, Na H, Wang JW, Song FL, Sun S, Wang DT, Wang MX, Wang XY, Wang YZ, Wang YD, Wu W, Wu LP, Xiao YH, Xie HJ, Xu HM, Xu SF, Xue RX, Yang C, Yang KJ, Yuan SL, Zhang GQ, Zhang JB, Zhang LS, Zhao SS, Zhao WY, Zheng K, Zhou YC, Zhu JT, Zhu TQ, Zhang HM, Wang YP, Wang YY; 'lung cleansing & detoxifying decoction' emergency project expert group for covid-19. Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China. Biomed Environ Sci 2020;33:893-905. [PMID: 33472729 DOI: 10.3967/bes2020.123] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Choudhary NS, Dhampalwar S, Saraf N, Soin AS. Outcomes of COVID-19 in Patients with Cirrhosis or Liver Transplantation. J Clin Exp Hepatol 2021. [PMID: 33994708 DOI: 10.1016/j.jceh.2021.05.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Tao Z, Li Y, Cheng B, Zhou T, Gao Y. Risk of Severe COVID-19 Increased by Metabolic Dysfunction-associated Fatty Liver Disease: A Meta-analysis. J Clin Gastroenterol 2021;55:830-5. [PMID: 34406175 DOI: 10.1097/MCG.0000000000001605] [Reference Citation Analysis]
42 McGrowder DA, Miller F, Anderson Cross M, Anderson-Jackson L, Bryan S, Dilworth L. Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. Diseases 2021;9:50. [PMID: 34287285 DOI: 10.3390/diseases9030050] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Hegyi PJ, Váncsa S, Ocskay K, Dembrovszky F, Kiss S, Farkas N, Erőss B, Szakács Z, Hegyi P, Pár G. Metabolic Associated Fatty Liver Disease Is Associated With an Increased Risk of Severe COVID-19: A Systematic Review With Meta-Analysis. Front Med (Lausanne) 2021;8:626425. [PMID: 33777974 DOI: 10.3389/fmed.2021.626425] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
44 Ozkurt Z, Çınar Tanrıverdi E. COVID-19: Gastrointestinal manifestations, liver injury and recommendations. World J Clin Cases 2022; 10(4): 1140-1163 [DOI: 10.12998/wjcc.v10.i4.1140] [Reference Citation Analysis]
45 Nasa P, Alexander G. COVID-19 and the liver: What do we know so far? World J Hepatol 2021; 13(5): 522-532 [PMID: 34131467 DOI: 10.4254/wjh.v13.i5.522] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Kullar R, Patel AP, Saab S. Hepatic Injury in Patients With COVID-19. Journal of Clinical Gastroenterology 2020;54:841-9. [DOI: 10.1097/mcg.0000000000001432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
47 Pan L, Huang P, Xie X, Xu J, Guo D, Jiang Y. Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis. Dig Liver Dis. 2021;53:153-157. [PMID: 33011088 DOI: 10.1016/j.dld.2020.09.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
48 Mikolasevic I, Bozic D, Pavić T, Ruzic A, Hauser G, Radic M, Radic-Kristo D, Razov-Radas M, Puljiz Z, Milic S. Liver disease in the era of COVID-19: Is the worst yet to come? World J Gastroenterol 2021; 27(36): 6039-6052 [PMID: 34629818 DOI: 10.3748/wjg.v27.i36.6039] [Reference Citation Analysis]
49 Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int 2021;41:20-32. [PMID: 33190346 DOI: 10.1111/liv.14730] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Wang M, Yan W, Qi W, Wu D, Zhu L, Li W, Wang X, Ma K, Ni M, Xu D, Wang H, Chen G, Yu H, Ding H, Xing M, Han M, Luo X, Chen T, Guo W, Xi D, Ning Q. Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China. Hepatol Int. 2020;14:723-732. [PMID: 33026573 DOI: 10.1007/s12072-020-10075-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
51 Bertolini A, van de Peppel IP, Bodewes FAJA, Moshage H, Fantin A, Farinati F, Fiorotto R, Jonker JW, Strazzabosco M, Verkade HJ, Peserico G. Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. Hepatology 2020;72:1864-72. [PMID: 32702162 DOI: 10.1002/hep.31480] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 32.0] [Reference Citation Analysis]
52 Assante G, Williams R, Youngson NA. Is the increased risk for MAFLD patients to develop severe COVID-19 linked to perturbation of the gut-liver axis? J Hepatol 2021;74:487-8. [PMID: 32574578 DOI: 10.1016/j.jhep.2020.05.051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
53 Miele L, Napodano C, Cesario A, De Magistris A, Pocino K, Basile U, Rapaccini GL, Gasbarrini A, Grieco A. COVID-19, adaptative immune response and metabolic-associated liver disease. Liver Int 2021;41:2560-77. [PMID: 34555255 DOI: 10.1111/liv.15061] [Reference Citation Analysis]
54 Lee A, Wein AN, Doyle MBM, Chapman WC. Liver transplantation for post-COVID-19 sclerosing cholangitis. BMJ Case Rep 2021;14:e244168. [PMID: 34446515 DOI: 10.1136/bcr-2021-244168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Palomar-Lever A, Barraza G, Galicia-Alba J, Echeverri-Bolaños M, Escarria-Panesso R, Padua-Barrios J, Halabe-Cherem J, Hernandez-Molina G, Chargoy-Loustaunau TN, Kimura-Hayama E. Hepatic steatosis as an independent risk factor for severe disease in patients with COVID-19: A computed tomography study. JGH Open 2020. [PMID: 32838045 DOI: 10.1002/jgh3.12395] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
56 Frater JL, Wang T, Lee Y. Laboratory hematologic features of COVID-19 associated liver injury: A systematic review. WJMA 2021;9:192-206. [DOI: 10.13105/wjma.v9.i2.192] [Reference Citation Analysis]
57 Ziaee A, Azarkar G, Ziaee M. Role of fatty liver in coronavirus disease 2019 patients' disease severity and hospitalization length: a case-control study. Eur J Med Res 2021;26:115. [PMID: 34565475 DOI: 10.1186/s40001-021-00590-y] [Reference Citation Analysis]
58 Wang X, Lei J, Li Z, Yan L. Potential Effects of Coronaviruses on the Liver: An Update. Front Med (Lausanne) 2021;8:651658. [PMID: 34646834 DOI: 10.3389/fmed.2021.651658] [Reference Citation Analysis]
59 Ji D, Zhang D, Yang T, Mu J, Zhao P, Xu J, Li C, Cheng G, Wang Y, Chen Z, Qin E, Lau G. Effect of COVID-19 on patients with compensated chronic liver diseases. Hepatol Int. 2020;14:701-710. [PMID: 32734407 DOI: 10.1007/s12072-020-10058-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
60 Sharma P, Kumar A. Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19. Diabetes Metab Syndr. 2020;14:825-827. [PMID: 32540736 DOI: 10.1016/j.dsx.2020.06.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
61 Shao J, Liang Y, Li Y, Ding R, Zhu M, You W, Wang Z, Huang B, Wu M, Zhang T, Li K, Wu W, Wu L, Wang Q, Xia X, Wang S, Lu L. Implications of liver injury in risk-stratification and management of patients with COVID-19. Hepatol Int. 2021;15:202-212. [PMID: 33548030 DOI: 10.1007/s12072-020-10123-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Łykowska-Szuber L, Wołodźko K, Rychter AM, Szymczak-Tomczak A, Krela-Kaźmierczak I, Dobrowolska A. Liver Injury in Patients with Coronavirus Disease 2019 (COVID-19)-A Narrative Review. J Clin Med 2021;10:5048. [PMID: 34768568 DOI: 10.3390/jcm10215048] [Reference Citation Analysis]
63 Signorello A, Lenci I, Milana M, Grassi G, Baiocchi L. COVID-19 in normal, diseased and transplanted liver. World J Gastroenterol 2021; 27(20): 2576-2585 [PMID: 34092976 DOI: 10.3748/wjg.v27.i20.2576] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
64 Madan K, Rastogi R, Bhargava R, Dagar V, Singla V, Sahu A, Singh P, Garg P, Aggarwal B, Singh RK. Is Fatty Liver associated with increased mortality and morbidity in patients with COVID-19 pneumonia? Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.04.013] [Reference Citation Analysis]
65 Wu ZH, Yang DL. A meta-analysis of the impact of COVID-19 on liver dysfunction. Eur J Med Res. 2020;25:54. [PMID: 33148326 DOI: 10.1186/s40001-020-00454-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
66 Verma HK, Bhaskar L. SARS-CoV-2 infection in people with pre-existing liver disease: Further research is warranted. World J Gastroenterol 2021; 27(45): 7855-7858 [PMID: 34963747 DOI: 10.3748/wjg.v27.i45.7855] [Reference Citation Analysis]
67 Saura N, Hernández M, Velamazán R, García S, Hijos G, Abad D, Alfaro E, Cañamares P, Martínez-Dominguez SJ, Laredo V, Borao C, Cortés L. Liver injury associated with SARS-CoV-2: A case report. Gastroenterol Hepatol 2021:S0210-5705(21)00200-4. [PMID: 34157369 DOI: 10.1016/j.gastrohep.2021.06.002] [Reference Citation Analysis]
68 Fiel MI, El Jamal SM, Paniz-Mondolfi A, Gordon RE, Reidy J, Bandovic J, Advani R, Kilaru S, Pourmand K, Ward S, Thung SN, Schiano T. Findings of Severe Hepatic Severe Acute Respiratory Syndrome Coronavirus-2 Infection. Cell Mol Gastroenterol Hepatol. 2021;1-8. [PMID: 32992052 DOI: 10.1016/j.jcmgh.2020.09.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
69 Guerra JVS, Dias MMG, Brilhante AJVC, Terra MF, García-Arévalo M, Figueira ACM. Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. Nutrients 2021;13:2830. [PMID: 34444990 DOI: 10.3390/nu13082830] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
70 Mallet V, Beeker N, Bouam S, Sogni P, Pol S; Demosthenes research group. Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020. J Hepatol 2021;75:848-55. [PMID: 33992699 DOI: 10.1016/j.jhep.2021.04.052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
71 Ridruejo E, Soza A. The liver in times of COVID-19: What hepatologists should know. Ann Hepatol. 2020;19:353-358. [PMID: 32425991 DOI: 10.1016/j.aohep.2020.05.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
72 Saviano A, Wrensch F, Ghany MG, Baumert TF. Liver disease and COVID-19: from Pathogenesis to Clinical Care. Hepatology. 2020;. [PMID: 33332624 DOI: 10.1002/hep.31684] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
73 Frisardi V. Commentary: Coronavirus and Obesity: Could Insulin Resistance Mediate the Severity of Covid-19 Infection? Front Public Health 2020;8:351. [PMID: 32733840 DOI: 10.3389/fpubh.2020.00351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Premkumar M, Kedarisetty CK. Cytokine Storm of COVID-19 and Its Impact on Patients with and without Chronic Liver Disease. J Clin Transl Hepatol 2021;9:256-64. [PMID: 34007808 DOI: 10.14218/JCTH.2021.00055] [Reference Citation Analysis]
75 Portincasa P, Krawczyk M, Machill A, Lammert F, Di Ciaula A. Hepatic consequences of COVID-19 infection. Lapping or biting? Eur J Intern Med. 2020;77:18-24. [PMID: 32507608 DOI: 10.1016/j.ejim.2020.05.035] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 17.5] [Reference Citation Analysis]
76 Fajar JK, Wibowo BP, Dewi GC, Rahmadi AP, Kusuma MT. Does MAFLD really increase the severity of COVID-19? Dig Liver Dis 2021;53:166-7. [PMID: 33208296 DOI: 10.1016/j.dld.2020.10.042] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Licata A, Minissale MG, Distefano M, Montalto G. Liver injury, SARS-COV-2 infection and COVID-19: What physicians should really know? GastroHep 2021;3:121-30. [PMID: 34149320 DOI: 10.1002/ygh2.455] [Reference Citation Analysis]
78 Ali A, Hasan M, Hamed S, Elhamy A. Hepatic steatosis: a risk factor for increased COVID-19 prevalence and severity-a computed tomography study. Egypt Liver J 2021;11:61. [PMID: 34777870 DOI: 10.1186/s43066-021-00131-6] [Reference Citation Analysis]
79 Murayama K, Okada M, Tanaka K, Inadomi C, Yoshioka W, Kubotsu Y, Yada T, Isoda H, Kuwashiro T, Oeda S, Akiyama T, Oza N, Hyogo H, Ono M, Kawaguchi T, Torimura T, Anzai K, Eguchi Y, Takahashi H. Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. Diagnostics (Basel) 2021;11:132. [PMID: 33467114 DOI: 10.3390/diagnostics11010132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
80 Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 mo of the pandemic. JHEP Rep. 2020;2:100169. [PMID: 32835190 DOI: 10.1016/j.jhepr.2020.100169] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 21.0] [Reference Citation Analysis]
81 Ji D, Qin E, Lau G. Reply to: 'Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis'. J Hepatol 2020;73:722. [PMID: 32437831 DOI: 10.1016/j.jhep.2020.05.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
82 Valenti L, Jamialahmadi O, Romeo S. Lack of genetic evidence that fatty liver disease predisposes to COVID-19. J Hepatol. 2020;73:709-711. [PMID: 32445883 DOI: 10.1016/j.jhep.2020.05.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
83 Rezasoltani S, Hatami B, Yadegar A, Asadzadeh Aghdaei H, Zali MR. How Patients With Chronic Liver Diseases Succeed to Deal With COVID-19? Front Med (Lausanne) 2020;7:398. [PMID: 32754608 DOI: 10.3389/fmed.2020.00398] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
84 Niriella MA, De Silva AP, Liyanage KI, Sarin SK, de Silva HJ. COVID-19 and gastroenterology: clinical insights and recommendations for gastroenterology care providers. Scand J Gastroenterol 2020;55:1005-11. [PMID: 32650675 DOI: 10.1080/00365521.2020.1789896] [Reference Citation Analysis]
85 Yao R, Zhu L, Wang J, Liu J, Xue R, Xue L, Liu L, Li C, Zhao H, Cheng J, Huang S, Li Y, Zhao XA, Zhu C, Li M, Huang R, Wu C. Risk of severe illness of COVID-19 patients with NAFLD and increased NAFLD fibrosis scores. J Clin Lab Anal 2021;35:e23880. [PMID: 34213039 DOI: 10.1002/jcla.23880] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
86 Jeyakumar SM, Vajreswari A. Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids. World J Clin Cases 2021; 9(31): 9333-9349 [PMID: 34877270 DOI: 10.12998/wjcc.v9.i31.9333] [Reference Citation Analysis]
87 Sharma P, Kumar A, Anikhindi S, Bansal N, Singla V, Shivam K, Arora A. Effect of COVID-19 on Pre-existing Liver disease: What Hepatologist Should Know? J Clin Exp Hepatol 2021;11:484-93. [PMID: 33398223 DOI: 10.1016/j.jceh.2020.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
88 Anirvan P, Singh SP, Giammarino A, Satapathy SK. Association of non-alcoholic fatty liver disease and COVID-19: A literature review of current evidence. World J Hepatol 2021; 13(8): 916-925 [PMID: 34552698 DOI: 10.4254/wjh.v13.i8.916] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Wang G, Wu S, Wu C, Zhang Q, Wu F, Yu B, Zhang S, Wu C, Wu G, Zhong Y. Association between non-alcoholic fatty liver disease with the susceptibility and outcome of COVID-19: A retrospective study. J Cell Mol Med 2021. [PMID: 34761514 DOI: 10.1111/jcmm.17042] [Reference Citation Analysis]
90 Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020;72:287-304. [PMID: 32298473 DOI: 10.1002/hep.31281] [Cited by in Crossref: 164] [Cited by in F6Publishing: 206] [Article Influence: 82.0] [Reference Citation Analysis]
91 Verma N, Duseja A, Singh V. Impact of Preexisting Chronic Liver Disease on the Outcome of Patients With COVID-19 Disease. Gastroenterology. 2021;160:1893-1894. [PMID: 32553766 DOI: 10.1053/j.gastro.2020.05.090] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
92 Chen VL, Hawa F, Berinstein JA, Reddy CA, Kassab I, Platt KD, Hsu CY, Steiner CA, Louissaint J, Gunaratnam NT, Sharma P. Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19. Dig Dis Sci. 2020;. [PMID: 32980956 DOI: 10.1007/s10620-020-06618-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
93 Campos-Murguía A, Román-Calleja BM, Toledo-Coronado IV, González-Regueiro JA, Solís-Ortega AA, Kúsulas-Delint D, Cruz-Contreras M, Cruz-Yedra N, Cubero FJ, Nevzorova YA, Martínez-Cabrera CF, Moreno-Guillén P, Lozano-Cruz OA, Chapa-Ibargüengoitia M, Gulías-Herrero A, Aguilar-Salinas CA, Ruiz-Margáin A, Macías-Rodríguez RU. Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19. Dig Liver Dis 2021;53:525-33. [PMID: 33551355 DOI: 10.1016/j.dld.2021.01.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
94 Neuman MG, Seitz HK, Teschke R, Malnick S, Johnson-davis KL, Cohen LB, German A, Hohmann N, Moreira B, Moussa G, Opris M. Molecular, Viral and Clinical Features of Alcohol- and Non-Alcohol-Induced Liver Injury. CIMB 2022;44:1294-315. [DOI: 10.3390/cimb44030087] [Reference Citation Analysis]
95 Zhang J, Liu F, Song T, Li Z, Xia P, Tang X, Xu M, Shen Y, Ma J, Liu X, Yu P. Liver Fibrosis Scores and Clinical Outcomes in Patients With COVID-19. Front Med 2022;9:829423. [DOI: 10.3389/fmed.2022.829423] [Reference Citation Analysis]
96 Oikonomou KG, Papamichalis P, Zafeiridis T, Xanthoudaki M, Papapostolou E, Valsamaki A, Bouliaris K, Papamichalis M, Karvouniaris M, Vlachostergios PJ, Skoura AL, Komnos A. Gastroenterology and liver disease during COVID-19 and in anticipation of post-COVID-19 era: Current practice and future directions. World J Clin Cases 2021; 9(19): 4918-4938 [PMID: 34307544 DOI: 10.12998/wjcc.v9.i19.4918] [Reference Citation Analysis]
97 Polyzos SA, Mantzoros CS. Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). Metabolism 2020;111S:154318. [PMID: 32707055 DOI: 10.1016/j.metabol.2020.154318] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
98 Sy-Janairo ML, Y Cua IH. Association of metabolic-associated fatty liver disease and risk of severe coronavirus disease 2019 illness.JGH Open. 2020;. [PMID: 33363258 DOI: 10.1002/jgh3.12465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
99 Wilke TJ, Fremming BA, Brown BA, Markin NW, Kassel CA. 2020 Clinical Update in Liver Transplantation. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00100-2. [PMID: 33653578 DOI: 10.1053/j.jvca.2021.02.005] [Reference Citation Analysis]
100 Mohandas S, Vairappan B. Severe acute respiratory syndrome coronavirus-2 infection and the gut-liver axis. J Dig Dis 2020;21:687-95. [PMID: 33099897 DOI: 10.1111/1751-2980.12951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
101 Lee YR, Kang MK, Song JE, Kim HJ, Kweon YO, Tak WY, Jang SY, Park JG, Lee C, Hwang JS, Jang BK, Suh JI, Chung WJ, Kim BS, Park SY. Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea. Clin Mol Hepatol. 2020;26:562-576. [PMID: 33053932 DOI: 10.3350/cmh.2020.0126] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
102 Herta T, Berg T. COVID-19 and the liver - Lessons learned. Liver Int. 2021;41 Suppl 1:1-8. [PMID: 34155789 DOI: 10.1111/liv.14854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Huang R, Zhu L, Wang J, Xue L, Liu L, Yan X, Huang S, Li Y, Yan X, Zhang B, Xu T, Li C, Ji F, Ming F, Zhao Y, Cheng J, Wang Y, Zhao H, Hong S, Chen K, Zhao XA, Zou L, Sang D, Shao H, Guan X, Chen X, Chen Y, Wei J, Zhu C, Wu C. Clinical features of COVID-19 patients with non-alcoholic fatty liver disease. Hepatol Commun 2020. [PMID: 32838108 DOI: 10.1002/hep4.1592] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
104 Costa FF, Rosário WR, Ribeiro Farias AC, de Souza RG, Duarte Gondim RS, Barroso WA. Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies. Diabetes Metab Syndr 2020;14:809-14. [PMID: 32540733 DOI: 10.1016/j.dsx.2020.06.016] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 21.5] [Reference Citation Analysis]
105 Chela HK, Pasha SB, Basar O, Daglilar E, Tahan V. Liver in the limelight in the corona (COVID-19) time. World J Clin Cases 2020; 8(16): 3405-3410 [PMID: 32913847 DOI: 10.12998/wjcc.v8.i16.3405] [Reference Citation Analysis]
106 Alkhouri N, Kohli A, Loomba R, Harrison SA. Maintaining Patient Safety and Data Integrity of Nonalcoholic Steatohepatitis Clinical Trials During the Severe Acute Respiratory Syndrome-Coronavirus 2 Pandemic. Hepatology 2020;72:1509-13. [PMID: 32794597 DOI: 10.1002/hep.31522] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 Dalamaga M, Christodoulatos GS, Karampela I, Vallianou N, Apovian CM. Understanding the Co-Epidemic of Obesity and COVID-19: Current Evidence, Comparison with Previous Epidemics, Mechanisms, and Preventive and Therapeutic Perspectives. Curr Obes Rep 2021. [PMID: 33909265 DOI: 10.1007/s13679-021-00436-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
108 Tahtabasi M, Hosbul T, Karaman E, Akin Y, Kilicaslan N, Gezer M, Sahiner F. Frequency of hepatic steatosis and its association with the pneumonia severity score on chest computed tomography in adult COVID-19 patients. World J Crit Care Med 2021; 10(3): 47-57 [PMID: 34046310 DOI: 10.5492/wjccm.v10.i3.47] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Abolfazli P, Aghajanzadeh T, Ghaderinasrabad M, Apue Nchama CN, Mokhlesi A, Talkhabi M. Bioinformatics analysis reveals molecular connections between non-alcoholic fatty liver disease (NAFLD) and COVID-19. J Cell Commun Signal 2022. [PMID: 35525888 DOI: 10.1007/s12079-022-00678-y] [Reference Citation Analysis]
110 Asemota J, Aduli F. The Impact of Nonalcoholic Fatty Liver Disease on the Outcomes of Coronavirus Disease 2019 Infection. Clinical Liver Disease 2022;19:29-31. [DOI: 10.1002/cld.1169] [Reference Citation Analysis]
111 Çoraplı M, Çil E, Oktay C, Kaçmaz H, Çoraplı G, Bulut HT. Role of hepatosteatosis in the prognosis of COVID 19 disease. Clin Imaging 2021;80:1-5. [PMID: 34214871 DOI: 10.1016/j.clinimag.2021.06.034] [Reference Citation Analysis]
112 Chang TH, Chou CC, Chang LY. Effect of obesity and body mass index on coronavirus disease 2019 severity: A systematic review and meta-analysis. Obes Rev 2020;21:e13089. [PMID: 32929833 DOI: 10.1111/obr.13089] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
113 Gato S, Lucena-Valera A, Muñoz-Hernández R, Sousa JM, Romero-Gómez M, Ampuero J. Impact of COVID-19 on liver disease: From the experimental to the clinic perspective. World J Virol 2021; 10(6): 301-311 [PMID: 34909404 DOI: 10.5501/wjv.v10.i6.301] [Reference Citation Analysis]
114 Lamadrid P, Alonso-Peña M, San Segundo D, Arias-Loste M, Crespo J, Lopez-Hoyos M. Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity. Front Immunol 2021;12:651728. [PMID: 33859644 DOI: 10.3389/fimmu.2021.651728] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Wang J, Hou Z, Liu J, Gu Y, Wu Y, Chen Z, Ji J, Diao S, Qiu Y, Zou S, Zhang A, Zhang N, Wang F, Li X, Wang Y, Liu X, Lv C, Chen S, Liu D, Ji X, Liu C, Ren T, Sun J, Zhao Z, Wu F, Li F, Wang R, Yan Y, Zhang S, Ge G, Shao J, Yang S, Liu C, Huang Y, Xu D, Li X, Ai J, He Q, Zheng MH, Zhang L, Xie Q, Rockey DC, Fallowfield JA, Zhang W, Qi X. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study. J Hepatol 2021;75:439-41. [PMID: 33905793 DOI: 10.1016/j.jhep.2021.04.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
116 Vinken M. COVID-19 and the liver: an adverse outcome pathway perspective. Toxicology 2021;455:152765. [PMID: 33771662 DOI: 10.1016/j.tox.2021.152765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
117 Abe K, Yamamoto T, Matsumoto K, Kikuchi K, Miura R, Tachizawa N, Asaoka Y, Takezawa T, Matsunaga N, Obi S, Tanaka A. Clinical Features and Liver Injury in Patients with COVID-19 in the Japanese Population. Intern Med. 2020;59:2353-2358. [PMID: 32999264 DOI: 10.2169/internalmedicine.5777-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
118 Da BL, Kushner T, El Halabi M, Paka P, Khalid M, Uberoi A, Lee BT, Perumalswami PV, Rutledge SM, Schiano TD, Friedman S, Saberi B. Liver Injury in Hospitalized Patients with COVID-19 Correlates with Hyper Inflammatory Response and Elevated IL-6. Hepatol Commun. 2020;. [PMID: 33230491 DOI: 10.1002/hep4.1631] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
119 Alarcon PC, Damen MSMA, Madan R, Deepe GS Jr, Spearman P, Way SS, Divanovic S. Adipocyte inflammation and pathogenesis of viral pneumonias: an overlooked contribution. Mucosal Immunol 2021. [PMID: 33958704 DOI: 10.1038/s41385-021-00404-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
120 Napodano C, Pocino K, Stefanile A, Marino M, Miele L, Gulli F, Basile V, Pandolfi F, Gasbarrini A, Rapaccini GL, Basile U. COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel. Scand J Immunol. 2021;93:e12977. [PMID: 32931622 DOI: 10.1111/sji.12977] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
121 Warner FJ, Rajapaksha H, Shackel N, Herath CB. ACE2: from protection of liver disease to propagation of COVID-19. Clin Sci (Lond). 2020;134:3137-3158. [PMID: 33284956 DOI: 10.1042/cs20201268] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
122 Shanmugam H, Di Ciaula A, Di Palo DM, Molina-Molina E, Garruti G, Faienza MF, vanErpecum K, Portincasa P. Multiplying effects of COVID-19 lockdown on metabolic risk and fatty liver. Eur J Clin Invest 2021;51:e13597. [PMID: 34032283 DOI: 10.1111/eci.13597] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
123 Mohammed A, Paranji N, Chen PH, Niu B. COVID-19 in Chronic Liver Disease and Liver Transplantation: A Clinical Review. J Clin Gastroenterol 2021;55:187-94. [PMID: 33394628 DOI: 10.1097/MCG.0000000000001481] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
124 Elhence A, Vaishnav M, Biswas S, Chauhan A, Anand A, Shalimar. Coronavirus Disease-2019 (COVID-19) and the Liver. J Clin Transl Hepatol 2021;9:247-55. [PMID: 34007807 DOI: 10.14218/JCTH.2021.00006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Fang LG, Zhou Q. Remarkable gastrointestinal and liver manifestations of COVID-19: A clinical and radiologic overview. World J Clin Cases 2021; 9(19): 4969-4979 [PMID: 34307547 DOI: 10.12998/wjcc.v9.i19.4969] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Marjot T, Webb GJ, Barritt AS 4th, Moon AM, Stamataki Z, Wong VW, Barnes E. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol 2021;18:348-64. [PMID: 33692570 DOI: 10.1038/s41575-021-00426-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 27.0] [Reference Citation Analysis]
127 Wang Q, Davis PB, Xu R. COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States. EClinicalMedicine. 2021;31:100688. [PMID: 33521611 DOI: 10.1016/j.eclinm.2020.100688] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
128 Cichoż-Lach H, Michalak A. Liver injury in the era of COVID-19. World J Gastroenterol 2021; 27(5): 377-390 [PMID: 33584070 DOI: 10.3748/wjg.v27.i5.377] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
129 Singh MK, Mobeen A, Chandra A, Joshi S, Ramachandran S. A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection? Comput Biol Med 2021;130:104219. [PMID: 33486379 DOI: 10.1016/j.compbiomed.2021.104219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
130 Ferron PJ, Gicquel T, Mégarbane B, Clément B, Fromenty B. Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury? Biochimie 2020;179:266-74. [PMID: 32891697 DOI: 10.1016/j.biochi.2020.08.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
131 Moctezuma-Velázquez P, Miranda-Zazueta G, Ortiz-Brizuela E, Garay-Mora JA, González-Lara MF, Tamez-Torres KM, Román-Montes CM, Díaz-Mejía BA, Pérez-García E, Villanueva-Reza M, Chapa-Ibargüengoitia M, Uscanga-Domínguez L, Sifuentes-Osornio J, Ponce-de-León A, Kershenobich-Stalnikowitz D, Mota-Ayala B, Moctezuma-Velázquez C. NAFLD determined by Dallas Steatosis Index is associated with poor outcomes in COVID-19 pneumonia: a cohort study. Intern Emerg Med 2022. [PMID: 35138548 DOI: 10.1007/s11739-022-02933-x] [Reference Citation Analysis]
132 Ahmed M, Ahmed MH. Nonalcoholic fatty liver disease and COVID-19: An epidemic that begets pandemic. World J Clin Cases 2021; 9(17): 4133-4142 [PMID: 34141776 DOI: 10.12998/wjcc.v9.i17.4133] [Reference Citation Analysis]
133 Han MW, Wang M, Xu MY, Qi WP, Wang P, Xi D. Clinical features and potential mechanism of coronavirus disease 2019-associated liver injury. World J Clin Cases 2021; 9(3): 528-539 [PMID: 33553391 DOI: 10.12998/wjcc.v9.i3.528] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
134 Vasques-Monteiro IML, Souza-Mello V. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight. World J Gastroenterol 2021; 27(16): 1738-1750 [PMID: 33967554 DOI: 10.3748/wjg.v27.i16.1738] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
135 Boraschi P, Giugliano L, Mercogliano G, Donati F, Romano S, Neri E. Abdominal and gastrointestinal manifestations in COVID-19 patients: Is imaging useful? World J Gastroenterol 2021; 27(26): 4143-4159 [PMID: 34326615 DOI: 10.3748/wjg.v27.i26.4143] [Reference Citation Analysis]
136 Ibáñez-Samaniego L, Bighelli F, Usón C, Caravaca C, Fernández Carrillo C, Romero M, Barreales M, Perelló C, Madejón A, Marcos AC, Albillos A, Fernández I, García-Samaniego J, Calleja JL, Bañares R. Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19.J Infect Dis. 2020;222:726-733. [PMID: 32563190 DOI: 10.1093/infdis/jiaa355] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
137 Nasa P, Alexander G. COVID-19 and the liver: What do we know so far? World J Hepatol 2021;13:522-32. [PMID: 34131467 DOI: 10.4254/wjh.v13.i5.522] [Reference Citation Analysis]
138 Chu H, Bai T, Chen L, Hu L, Xiao L, Yao L, Zhu R, Niu X, Li Z, Zhang L, Han C, Song S, He Q, Zhao Y, Zhu Q, Chen H, Schnabl B, Yang L, Hou X. Multicenter Analysis of Liver Injury Patterns and Mortality in COVID-19. Front Med (Lausanne). 2020;7:584342. [PMID: 33195339 DOI: 10.3389/fmed.2020.584342] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
139 Calapod OP, Marin AM, Onisai M, Tribus LC, Pop CS, Fierbinteanu-Braticevici C. The Impact of Increased Fib-4 Score in Patients with Type II Diabetes Mellitus on Covid-19 Disease Prognosis. Medicina (Kaunas) 2021;57:434. [PMID: 33946377 DOI: 10.3390/medicina57050434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Branch AD. How to Survive COVID-19 Even If the Vaccine Fails. Hepatol Commun 2020;4:1864-79. [PMID: 33305156 DOI: 10.1002/hep4.1588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
141 Alyammahi SK, Abdin SM, Alhamad DW, Elgendy SM, Altell AT, Omar HA. The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities. Infect Genet Evol 2021;87:104647. [PMID: 33264669 DOI: 10.1016/j.meegid.2020.104647] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
142 Vaidya T, Nanivadekar A, Patel R. Imaging spectrum of abdominal manifestations of COVID-19. World J Radiol 2021; 13(6): 157-170 [PMID: 34249237 DOI: 10.4329/wjr.v13.i6.157] [Reference Citation Analysis]
143 Wu ZH, Yang DL. A meta-analysis of the impact of COVID-19 on liver dysfunction. Eur J Med Res 2020;25:54. [PMID: 33148326 DOI: 10.1186/s40001-020-00454-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 1] [Article Influence: 10.0] [Reference Citation Analysis]
144 Biquard L, Valla D, Rautou PE. No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease. J Hepatol 2020;73:717-8. [PMID: 32360995 DOI: 10.1016/j.jhep.2020.04.035] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
145 APASL Covid-19 Task Force. Lau G, Sharma M. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hepatol Int. 2020;14:415-428. [PMID: 32447721 DOI: 10.1007/s12072-020-10054-w] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 15.0] [Reference Citation Analysis]
146 Mazzolini G, Sowa JP, Atorrasagasti C, Kücükoglu Ö, Syn WK, Canbay A. Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. Cells 2020;9:E2458. [PMID: 33187255 DOI: 10.3390/cells9112458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
147 Liu D, Zhang Q, Bai P, Zhao J. Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease. J Hepatol 2021:S0168-8278(21)02218-2. [PMID: 34813919 DOI: 10.1016/j.jhep.2021.11.014] [Reference Citation Analysis]
148 Peck-Radosavljevic M, Burra P, Ferret MB, Fracasso P, Ricciardiello L, Seufferlein T, Van Hootegem P, van Leerdam M, Zelber-Sagi S; UEG Public Affairs Committee. COVID-19 and digestive health: Implications for prevention, care and the use of COVID-19 vaccines in vulnerable patients. United European Gastroenterol J 2021;9:1091-5. [PMID: 34716760 DOI: 10.1002/ueg2.12173] [Reference Citation Analysis]
149 Portincasa P, Krawczyk M, Smyk W, Lammert F, Di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics. Eur J Clin Invest. 2020;50:e13338. [PMID: 32589264 DOI: 10.1111/eci.13338] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 12.5] [Reference Citation Analysis]
150 Alkattan W, Yaqinuddin A, Shafqat A, Kashir J. NET-Mediated Pathogenesis of COVID-19: The Role of NETs in Hepatic Manifestations. Journal of Health and Allied Sciences NU. [DOI: 10.1055/s-0041-1741418] [Reference Citation Analysis]
151 Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int. 2021;41:20-32. [PMID: 33190346 DOI: 10.1111/liv.14730] [Cited by in Crossref: 36] [Cited by in F6Publishing: 46] [Article Influence: 18.0] [Reference Citation Analysis]
152 Téllez L, Martín Mateos RM. COVID-19 and liver disease: An update. Gastroenterol Hepatol 2020;43:472-80. [PMID: 32727662 DOI: 10.1016/j.gastrohep.2020.06.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
153 Sarin SK, Choudhury A, Lau GK, Zheng MH, Ji D, Abd-Elsalam S, Hwang J, Qi X, Cua IH, Suh JI, Park JG, Putcharoen O, Kaewdech A, Piratvisuth T, Treeprasertsuk S, Park S, Wejnaruemarn S, Payawal DA, Baatarkhuu O, Ahn SH, Yeo CD, Alonzo UR, Chinbayar T, Loho IM, Yokosuka O, Jafri W, Tan S, Soo LI, Tanwandee T, Gani R, Anand L, Esmail ES, Khalaf M, Alam S, Lin CY, Chuang WL, Soin AS, Garg HK, Kalista K, Batsukh B, Purnomo HD, Dara VP, Rathi P, Al Mahtab M, Shukla A, Sharma MK, Omata M;  APASL COVID Task Force; APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640). Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int. 2020;14:690-700. [PMID: 32623632 DOI: 10.1007/s12072-020-10072-8] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 29.5] [Reference Citation Analysis]
154 Garrido M, Pereira Guedes T, Alves Silva J, Falcão D, Novo I, Archer S, Rocha M, Maia L, Sarmento-Castro R, Pedroto I. Impact of Liver Test Abnormalities and Chronic Liver Disease on the Clinical Outcomes of Patients Hospitalized with COVID-19. GE Port J Gastroenterol 2021;158:1-12. [PMID: 34192127 DOI: 10.1159/000513593] [Reference Citation Analysis]
155 Garrido I, Liberal R, Macedo G. Review article: COVID-19 and liver disease-what we know on 1st May 2020. Aliment Pharmacol Ther. 2020;52:267-275. [PMID: 32402090 DOI: 10.1111/apt.15813] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 31.0] [Reference Citation Analysis]
156 Jaffe A, Schilsky ML, Deshpande R, Batra R. Liver Transplantation in the Time of COVID19: Barriers and Ethical considerations for Management and Next Steps. Hepatol Commun. 2020;. [PMID: 32838103 DOI: 10.1002/hep4.1568] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
157 Parlak S, Çıvgın E, Beşler MS, Kayıpmaz AE. The effect of hepatic steatosis on COVID-19 severity: Chest computed tomography findings. Saudi J Gastroenterol 2021;27:105-10. [PMID: 33642355 DOI: 10.4103/sjg.sjg_540_20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
158 Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Sirinawasatien A, Chantarojanasiri T, Ekpanyapong S, Tivatunsakul N, Luvira V. Coronavirus disease 2019 gastrointestinal and liver manifestations in adults: A review. JGH Open 2021;5:1257-65. [PMID: 34816011 DOI: 10.1002/jgh3.12671] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Saviano A, Baumert TF. Unraveling the role of liver sinusoidal endothelial cells in COVID-19 liver injury. J Hepatol 2021;75:503-5. [PMID: 34274367 DOI: 10.1016/j.jhep.2021.07.008] [Reference Citation Analysis]
161 Ji D, Cheng G, Lau G. Reply to: "NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues". J Hepatol 2021;74:484-5. [PMID: 33130185 DOI: 10.1016/j.jhep.2020.10.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
162 Ahmad Z, Goswami S, Paneerselvam A, Kabilan K, Chowdhury H, Roy A, Guleria R, Soni KD, Baruah U, Das CJ. Imaging of Coronavirus Disease 2019 Infection From Head to Toe: A Primer for the Radiologist. Curr Probl Diagn Radiol 2021:S0363-0188(21)00113-4. [PMID: 34330569 DOI: 10.1067/j.cpradiol.2021.06.015] [Reference Citation Analysis]
163 Fondevila MF, Mercado-Gómez M, Rodríguez A, Gonzalez-Rellan MJ, Iruzubieta P, Valentí V, Escalada J, Schwaninger M, Prevot V, Dieguez C, Crespo J, Frühbeck G, Martinez-Chantar ML, Nogueiras R. Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points. J Hepatol 2021;74:469-71. [PMID: 33096086 DOI: 10.1016/j.jhep.2020.09.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
164 Islam SRU, Akther T, Sultana S, Munshi SU. Persistence of SARS-CoV-2 RNA in a male with metabolic syndrome for 72 days: A case report. SAGE Open Med Case Rep 2021;9:2050313X21989492. [PMID: 33628449 DOI: 10.1177/2050313X21989492] [Reference Citation Analysis]
165 Sweed D, Abdelsameea E, Khalifa EA, Abdallah H, Moaz H, Moaz I, Abdelsattar S, Abdel-Rahman N, Mosbeh A, Elmahdy HA, Sweed E. SARS-CoV-2-associated gastrointestinal and liver diseases: what is known and what is needed to explore. Egypt Liver J 2021;11:64. [PMID: 34777871 DOI: 10.1186/s43066-021-00123-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Ahmad A, Ishtiaq SM, Khan JA, Aslam R, Ali S, Arshad MI. COVID-19 and comorbidities of hepatic diseases in a global perspective. World J Gastroenterol 2021; 27(13): 1296-1310 [PMID: 33833483 DOI: 10.3748/wjg.v27.i13.1296] [Reference Citation Analysis]
167 Omar AS, Kaddoura R, Orabi B, Hanoura S. Impact of COVID-19 pandemic on liver, liver diseases, and liver transplantation programs in intensive care units. World J Hepatol 2021; 13(10): 1215-1233 [PMID: 34786163 DOI: 10.4254/wjh.v13.i10.1215] [Reference Citation Analysis]
168 Frater JL, Wang T, Lee YS. Laboratory hematologic features of COVID-19 associated liver injury: A systematic review. World J Meta-Anal 2021; 9(2): 193-207 [DOI: 10.13105/wjma.v9.i2.193] [Reference Citation Analysis]
169 Demirtas CO, Keklikkiran C, Ergenc I, Erturk Sengel B, Eskidemir G, Cinel I, Odabasi Z, Korten V, Yilmaz Y. Liver stiffness is associated with disease severity and worse clinical scenarios in coronavirus disease 2019: A prospective transient elastography study. Int J Clin Pract 2021;75:e14363. [PMID: 33993597 DOI: 10.1111/ijcp.14363] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Phipps MM, Verna EC. Coronavirus Disease 2019 and Liver Transplantation: Lessons from the First Year of the Pandemic. Liver Transpl 2021;27:1312-25. [PMID: 34096188 DOI: 10.1002/lt.26194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Gupta M, Manek G, Dombrowski K, Maiwall R. Newer developments in viral hepatitis: Looking beyond hepatotropic viruses. World J Meta-Anal 2021; 9(6): 522-542 [DOI: 10.13105/wjma.v9.i6.522] [Reference Citation Analysis]
172 Romero-Cristóbal M, Clemente-Sánchez A, Piñeiro P, Cedeño J, Rayón L, Del Río J, Ramos C, Hernández DA, Cova M, Caballero A, Garutti I, García-Olivares P, Hortal J, Guerrero JE, García R, Bañares R, Rincón D. Possible unrecognised liver injury is associated with mortality in critically ill COVID-19 patients. Therap Adv Gastroenterol 2021;14:17562848211023410. [PMID: 34178116 DOI: 10.1177/17562848211023410] [Reference Citation Analysis]
173 Di Sessa A, Lanzaro F, Zarrilli S, Picone V, Guarino S, Miraglia del Giudice E, Marzuillo P. COVID-19 and pediatric fatty liver disease: Is there interplay? World J Gastroenterol 2021; 27(22): 3064-3072 [PMID: 34168408 DOI: 10.3748/wjg.v27.i22.3064] [Reference Citation Analysis]
174 Lopez-Mendez I, Aquino-Matus J, Gall SM, Prieto-Nava JD, Juarez-Hernandez E, Uribe M, Castro-Narro G. Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19). Ann Hepatol. 2021;20:100271. [PMID: 33099028 DOI: 10.1016/j.aohep.2020.09.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
175 Zaky S, Alboraie M, El Badry M, Metwally MA, Abdelaziz A, Fouad Y, Abd-Elsalam S, Mahmoud A, Shiha G, Baki AA, El Kassas M, Esmat G. Management of liver disease patients in different clinical situations during COVID-19 pandemic. Egypt Liver J 2021;11:21. [PMID: 34777868 DOI: 10.1186/s43066-021-00091-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
176 Liu M, Gao Y, Shi S, Chen Y, Yang K, Tian J. Drinking no-links to the severity of COVID-19: a systematic review and meta-analysis. J Infect 2020;81:e126-7. [PMID: 32474047 DOI: 10.1016/j.jinf.2020.05.042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
177 Abdelmohsen MA, Alkandari BM, Gupta VK, Elbeheiry AA. Diagnostic value of abdominal sonography in confirmed COVID-19 intensive care patients. Egypt J Radiol Nucl Med 2020;51. [DOI: 10.1186/s43055-020-00317-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
178 Kushner T, Cafardi J. Chronic Liver Disease and COVID-19: Alcohol Use Disorder/Alcohol-Associated Liver Disease, Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Autoimmune Liver Disease, and Compensated Cirrhosis. Clin Liver Dis (Hoboken). 2020;15:195-199. [PMID: 32537135 DOI: 10.1002/cld.974] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
179 Williams R, Alessi C, Alexander G, Allison M, Aspinall R, Batterham RL, Bhala N, Day N, Dhawan A, Drummond C, Ferguson J, Foster G, Gilmore I, Goldacre R, Gordon H, Henn C, Kelly D, MacGilchrist A, McCorry R, McDougall N, Mirza Z, Moriarty K, Newsome P, Pinder R, Roberts S, Rutter H, Ryder S, Samyn M, Severi K, Sheron N, Thorburn D, Verne J, Williams J, Yeoman A. New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK. Lancet 2021;397:1770-80. [PMID: 33714360 DOI: 10.1016/S0140-6736(20)32396-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Forlano R, Mullish BH, Mukherjee SK, Nathwani R, Harlow C, Crook P, Judge R, Soubieres A, Middleton P, Daunt A, Perez-Guzman P, Selvapatt N, Lemoine M, Dhar A, Thursz MR, Nayagam S, Manousou P. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS One. 2020;15:e0240400. [PMID: 33031439 DOI: 10.1371/journal.pone.0240400] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
181 Lee YR. Management of Patients with Chronic Liver Disease: The Era of the COVID-19 Pandemic. Korean J Gastroenterol 2021;77:156-9. [DOI: 10.4166/kjg.2021.402] [Reference Citation Analysis]
182 O'Gorman P, Norris S. Exercising in the COVID-19 era: implications in non-alcoholic fatty liver disease (NAFLD). BMJ Open Gastroenterol 2021;8:e000568. [PMID: 34168043 DOI: 10.1136/bmjgast-2020-000568] [Reference Citation Analysis]
183 Salamanna F, Maglio M, Landini MP, Fini M. Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2. Front Med (Lausanne) 2020;7:594495. [PMID: 33344479 DOI: 10.3389/fmed.2020.594495] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
184 Zelenika M, Lucijanic M, Bokun T, Bozin T, Barisic Jaman M, Tjesic Drinkovic I, Pastrovic F, Madir A, Luksic I, Piskac Zivkovic N, Luetic K, Krznaric Z, Ostojic R, Filipec Kanizaj T, Bogadi I, Virovic Jukic L, Kukla M, Grgurevic I. FibroScan-AST Score Predicts 30-Day Mortality or Need for Mechanical Ventilation among Patients Hospitalized with COVID-19. J Clin Med 2021;10:4355. [PMID: 34640373 DOI: 10.3390/jcm10194355] [Reference Citation Analysis]
185 Sahu T, Mehta A, Ratre YK, Jaiswal A, Vishvakarma NK, Bhaskar LVKS, Verma HK. Current understanding of the impact of COVID-19 on gastrointestinal disease: Challenges and openings. World J Gastroenterol 2021; 27(6): 449-469 [PMID: 33642821 DOI: 10.3748/wjg.v27.i6.449] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
186 Anirvan P, Bharali P, Gogoi M, Thuluvath PJ, Singh SP, Satapathy SK. Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome — what we know so far. World J Hepatol 2020; 12(12): 1182-1197 [PMID: 33442447 DOI: 10.4254/wjh.v12.i12.1182] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
187 Campos-Murguía A, Román-Calleja BM, González-Regueiro JA, Hurtado-Díaz-de-León I, Solís-Ortega AA, Flores-García NC, García-Juárez I, Ruiz-Margáin A, Macías-Rodríguez RU. Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19. World J Gastroenterol 2021; 27(33): 5502-5519 [PMID: 34588748 DOI: 10.3748/wjg.v27.i33.5502] [Reference Citation Analysis]
188 Nayak B, Lal G, Kumar S, Das CJ, Saraya A, Shalimar. Host Response to SARS-CoV2 and Emerging Variants in Pre-Existing Liver and Gastrointestinal Diseases. Front Cell Infect Microbiol 2021;11:753249. [PMID: 34760721 DOI: 10.3389/fcimb.2021.753249] [Reference Citation Analysis]
189 Chu H, Peng L, Hu L, Zhu Y, Zhao J, Su H, Yao L, Zhu Q, Nie X, Yang L, Hou X. Liver Histopathological Analysis of 24 Postmortem Findings of Patients With COVID-19 in China. Front Med (Lausanne) 2021;8:749318. [PMID: 34708059 DOI: 10.3389/fmed.2021.749318] [Reference Citation Analysis]
190 Lozano-Sepulveda SA, Galan-Huerta K, Martínez-Acuña N, Arellanos-Soto D, Rivas-Estilla AM. SARS-CoV-2 another kind of liver aggressor, how does it do that? Ann Hepatol 2020;19:592-6. [PMID: 32858226 DOI: 10.1016/j.aohep.2020.08.062] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
191 Dawood RM, Salum GM, El-Meguid MA. The Impact of COVID-19 on Liver Injury: COVID-19 and Liver Injury. Am J Med Sci 2021:S0002-9629(21)00400-6. [PMID: 34752738 DOI: 10.1016/j.amjms.2021.11.001] [Reference Citation Analysis]
192 Ponziani FR, Gasbarrini A, Pompili M. NAFLD or comorbidities, that is the question. J Hepatol 2020;73:723. [PMID: 32333924 DOI: 10.1016/j.jhep.2020.04.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
193 Dongiovanni P, Meroni M, Longo M, Fracanzani AL. MAFLD in COVID-19 patients: an insidious enemy. Expert Review of Gastroenterology & Hepatology 2020;14:867-72. [DOI: 10.1080/17474124.2020.1801417] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
194 Ali FEM, Mohammedsaleh ZM, Ali MM, Ghogar OM. Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges. World J Gastroenterol 2021; 27(15): 1531-1552 [PMID: 33958841 DOI: 10.3748/wjg.v27.i15.1531] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
195 Trivedi HD, Wilechansky R, Goyes D, Vieira Barbosa J, Canakis A, Lai M, Long MT, Fricker Z. Radiographic Hepatic Steatosis Is Not Associated With Key Clinical Outcomes Among Patients Hospitalized With COVID-19. Gastroenterology Res 2021;14:179-83. [PMID: 34267833 DOI: 10.14740/gr1389] [Reference Citation Analysis]
196 Quagliariello V, Bonelli A, Caronna A, Conforti G, Iovine M, Carbone A, Berretta M, Botti G, Maurea N. SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients. Cancers (Basel) 2020;12:E3316. [PMID: 33182653 DOI: 10.3390/cancers12113316] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
197 Chen LY, Chu HK, Bai T, Tu SJ, Wei Y, Li ZL, Hu LL, Zhu R, Zhang L, Han CQ, Xiao L, He Q, Song J, Liu WH, Zhu QJ, Chen H, Yang L, Hou XH. Liver damage at admission is an independent prognostic factor for COVID-19. J Dig Dis. 2020;21:512-518. [PMID: 32713118 DOI: 10.1111/1751-2980.12925] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
198 Tripon S, Bilbault P, Fabacher T, Lefebvre N, Lescuyer S, Andres E, Schmitt E, Garnier-kepka S, Borgne PL, Muller J, Merdji H, Chaffraix F, Mutter D, Baumert TF, Meziani F, Doffoel M. Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with Covid-19. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.101894] [Reference Citation Analysis]
199 Mani I, Alexopoulou A. Recent challenges facing patients with preexisting chronic liver disease in the era of the COVID-19 pandemic. Ann Gastroenterol 2021;34:625-33. [PMID: 34475732 DOI: 10.20524/aog.2021.0628] [Reference Citation Analysis]
200 Taylor R 3rd, Mallon D. COVID-19 and Pediatric Gastroenterology. Pediatr Clin North Am 2021;68:1157-69. [PMID: 34736582 DOI: 10.1016/j.pcl.2021.07.003] [Reference Citation Analysis]
201 Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: Discovery, diagnostics and drug development. J Hepatol. 2021;74:168-184. [PMID: 33038433 DOI: 10.1016/j.jhep.2020.09.031] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 29.5] [Reference Citation Analysis]
202 Ji D, Zhang D, Lau G. Reply to: 'NAFLD or comorbidities, that is the question'. J Hepatol 2020;73:724-5. [PMID: 32407814 DOI: 10.1016/j.jhep.2020.05.006] [Reference Citation Analysis]
203 Di Giorgio A, Hartleif S, Warner S, Kelly D. COVID-19 in Children With Liver Disease. Front Pediatr 2021;9:616381. [PMID: 33777864 DOI: 10.3389/fped.2021.616381] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
204 Wang J, Zhu L, Xue L, Liu L, Yan X, Huang S, Zhang B, Xu T, Li C, Ji F, Ming F, Zhao Y, Cheng J, Shao H, Chen K, Zhao XA, Sang D, Zhao H, Guan X, Chen X, Chen Y, Liu J, Huang R, Zhu C, Wu C. Risk factors of liver injury in patients with coronavirus disease 2019 in Jiangsu, China: A retrospective, multi-center study. J Med Virol. 2020;. [PMID: 33174624 DOI: 10.1002/jmv.26663] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
205 Agarwal L, Agarwal A, Advani S, Katiyar V, Chaturvedi A, Madhusudhan KS. The eyes see what the mind seeks: a systematic review of abdominal imaging findings in patients with COVID-19. Br J Radiol 2021;94:20201220. [PMID: 34260323 DOI: 10.1259/bjr.20201220] [Reference Citation Analysis]
206 Martinez MA, Franco S. Impact of COVID-19 in Liver Disease Progression. Hepatol Commun 2021. [PMID: 34222744 DOI: 10.1002/hep4.1745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
207 Yang RX, Zheng RD, Fan JG. Etiology and management of liver injury in patients with COVID-19. World J Gastroenterol 2020; 26(32): 4753-4762 [PMID: 32921955 DOI: 10.3748/wjg.v26.i32.4753] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
208 Levy E, Stintzi A, Cohen A, Desjardins Y, Marette A, Spahis S. Critical appraisal of the mechanisms of gastrointestinal and hepatobiliary infection by COVID-19. Am J Physiol Gastrointest Liver Physiol 2021;321:G99-G112. [PMID: 34009033 DOI: 10.1152/ajpgi.00106.2021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
209 Han Q, Lu Y, Wang D, Zhao Y, Li X, Mei N, Zhu Y, Xiao A, Yin B. Assessment of dynamic hepatic and renal imaging changes in COVID-19 survivors using T1 mapping and IVIM-DWI. Abdom Radiol. [DOI: 10.1007/s00261-022-03471-y] [Reference Citation Analysis]
210 Zhai G, Li M, Wang Y, Wu J. Drug-Induced Liver Disturbance During the Treatment of COVID-19. Front Pharmacol 2021;12:719308. [PMID: 34483929 DOI: 10.3389/fphar.2021.719308] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
211 Spearman CW, Aghemo A, Valenti L, Sonderup MW. COVID-19 and the liver: A 2021 update. Liver Int 2021;41:1988-98. [PMID: 34152690 DOI: 10.1111/liv.14984] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
212 Xiang TD, Zheng X. Interaction between hepatitis B virus and SARS-CoV-2 infections. World J Gastroenterol 2021; 27(9): 782-793 [PMID: 33727770 DOI: 10.3748/wjg.v27.i9.782] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
213 Ji D, Qin E, Zhang D, Cheng G, Lau G. Reply to Grifoni et al. Clin Infect Dis 2021;72:183. [PMID: 33034344 DOI: 10.1093/cid/ciaa699] [Reference Citation Analysis]
214 Fedele D, De Francesco A, Riso S, Collo A. Obesity, malnutrition, and trace element deficiency in the coronavirus disease (COVID-19) pandemic: An overview.Nutrition. 2021;81:111016. [PMID: 33059127 DOI: 10.1016/j.nut.2020.111016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
215 Gracia-Ramos AE, Jaquez-Quintana JO, Contreras-Omaña R, Auron M. Liver dysfunction and SARS-CoV-2 infection. World J Gastroenterol 2021; 27(26): 3951-3970 [PMID: 34326607 DOI: 10.3748/wjg.v27.i26.3951] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
216 Cai Y, Ye LP, Song YQ, Mao XL, Wang L, Jiang YZ, Que WT, Li SW. Liver injury in COVID-19: Detection, pathogenesis, and treatment. World J Gastroenterol 2021; 27(22): 3022-3036 [PMID: 34168405 DOI: 10.3748/wjg.v27.i22.3022] [Reference Citation Analysis]
217 Acehan S, Gülen M, Isikber C, Kaya A, Unlu N, Ince C, Toptas Firat B, Koksaldi G, Sümbül HE, Satar S. C-reactive protein to albumin ratio is associated with increased risk of mortality in COVID-19 pneumonia patients. Cukurova Medical Journal 2021;46:1449-58. [DOI: 10.17826/cumj.977050] [Reference Citation Analysis]
218 Roca-Fernández A, Dennis A, Nicholls R, McGonigle J, Kelly M, Banerjee R, Banerjee A, Sanyal AJ. Hepatic Steatosis, Rather Than Underlying Obesity, Increases the Risk of Infection and Hospitalization for COVID-19. Front Med (Lausanne) 2021;8:636637. [PMID: 33855033 DOI: 10.3389/fmed.2021.636637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
219 Li D, Ding X, Xie M, Tian D, Xia L. COVID-19-associated liver injury: from bedside to bench. J Gastroenterol. 2021;56:218-230. [PMID: 33527211 DOI: 10.1007/s00535-021-01760-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
220 Vranić L, Radovan A, Poropat G, Mikolašević I, Milić S. Non-Alcoholic Fatty Liver Disease and COVID-19-Two Pandemics Hitting at the Same Time. Medicina (Kaunas) 2021;57:1057. [PMID: 34684094 DOI: 10.3390/medicina57101057] [Reference Citation Analysis]
221 Singh A, Hussain S, Antony B. Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis. Diabetes Metab Syndr 2021;15:813-22. [PMID: 33862417 DOI: 10.1016/j.dsx.2021.03.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
222 Siparsky N. The Juice Versus the Squeeze. Crit Care Med 2021;49:716-8. [PMID: 33731614 DOI: 10.1097/CCM.0000000000004857] [Reference Citation Analysis]
223 Chang Y, Jeon J, Song T, Kim J. Association between the fatty liver index and the risk of severe complications in COVID-19 patients: a nationwide retrospective cohort study. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07370-x] [Reference Citation Analysis]
224 Di Giorgio A, Nicastro E, Arnaboldi S, Montini O, Di Stasio F, D'Antiga L, Gaio P, Fovino LN, Cananzi M, Pinon M, Calvo PL, Camelli V. "Health status of children with chronic liver disease during the SARS-CoV-2 outbreak: results from a multicentre study". Clin Res Hepatol Gastroenterol 2021;45:101610. [PMID: 33588313 DOI: 10.1016/j.clinre.2020.101610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
225 Evans RM, Lippman SM. Shining Light on the COVID-19 Pandemic: A Vitamin D Receptor Checkpoint in Defense of Unregulated Wound Healing. Cell Metab. 2020;32:704-709. [PMID: 32941797 DOI: 10.1016/j.cmet.2020.09.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
226 Targher G, Mantovani A, Byrne CD, Wang XB, Yan HD, Sun QF, Pan KH, Zheng KI, Chen YP, Eslam M, George J, Zheng MH. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020;69:1545-1547. [PMID: 32414813 DOI: 10.1136/gutjnl-2020-321611] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 27.0] [Reference Citation Analysis]